Revolution Medicines, Inc.
RVMDNasdaqCIK 1628171HealthcareFiscal year ends Dec 31
Reports and events: 111 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-1316:32 ET | 8-K | 2.03 New direct financial obligation; 8.01 Other events | 0001628171-26-000004 |
| 2026-09-0106:00 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001193125-26-377362 |
| 2026-08-2613:33 ET | 8-K | 8.01 Other events | 0001193125-26-366931 |
| 2026-08-0516:10 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-335104 |
| 2026-08-0516:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-335039 |
| 2026-06-2208:00 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001193125-26-276718 |
| 2026-05-0616:10 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-208969 |
| 2026-05-0616:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-208918 |
| 2026-04-2717:30 ET | DEF 14A | Proxy statementPeriod 2026-06-18 | 0001193125-26-182453 |
| 2026-04-1717:16 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-161800 |
| 2026-04-1617:06 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-159289 |
| 2026-04-1308:25 ET | 8-K | 8.01 Other events | 0001193125-26-152039 |
| 2026-02-2516:11 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-071563 |
| 2026-02-2516:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-071517 |
| 2025-11-0516:10 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-266923 |
| 2025-11-0516:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-266836 |
| 2025-10-1720:27 ET | 8-K | 8.01 Other events | 0001193125-25-241736 |
| 2025-09-1016:05 ET | 8-K | 8.01 Other events | 0001193125-25-200078 |
| 2025-08-0616:11 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-104022 |
| 2025-08-0616:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-103983 |
| 2025-06-2716:05 ET | 8-K | 5.07 Shareholder vote results | 0001193125-25-151254 |
| 2025-06-2407:05 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-145242 |
| 2025-06-1816:23 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-142735 |
| 2025-05-0716:10 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-065660 |
| 2025-05-0716:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-065618 |
| 2025-04-2916:38 ET | DEF 14A | Proxy statementPeriod 2025-06-26 | 0001193125-25-103947 |
| 2025-02-2616:10 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-027736 |
| 2025-02-2616:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-027707 |
| 2024-12-0516:18 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-271540 |
| 2024-12-0207:30 ET | 8-K | 8.01 Other events | 0001193125-24-268404 |
| 2024-11-0616:10 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-122303 |
| 2024-11-0616:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-122266 |
| 2024-10-2506:43 ET | 8-K | 8.01 Other events | 0001193125-24-243431 |
| 2024-10-2306:05 ET | 8-K | 8.01 Other events | 0001193125-24-241397 |
| 2024-08-0716:10 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-092783 |
| 2024-08-0716:05 ET | 8-K | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-24-092735 |
| 2024-07-1508:03 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-178836 |
| 2024-06-2416:06 ET | 8-K | 5.07 Shareholder vote results | 0001193125-24-166939 |
| 2024-05-0816:11 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-055655 |
| 2024-05-0816:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-055606 |
| 2024-04-2516:30 ET | DEF 14A | Proxy statementPeriod 2024-04-25 | 0000950170-24-048380 |
| 2024-02-2616:08 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-020145 |
| 2024-02-2616:04 ET | 8-K | 2.02 Results of operations | 0000950170-24-020125 |
| 2024-01-0914:15 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-005061 |
| 2023-12-2617:45 ET | 8-K/A | 9.01 Financial statements and exhibits | 0001193125-23-302252 |
| 2023-11-0909:20 ET | 8-K | 2.01 Completion of an acquisition or disposition; 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-23-274137 |
| 2023-11-0616:09 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-059391 |
| 2023-11-0616:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-059374 |
| 2023-11-0107:08 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-267696 |
| 2023-10-2306:11 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-260299 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 30, 2026, 12:38 ET. Listed shows no prices and gives no investment advice.